Skip to main content

CORRECTION article

Front. Pharmacol., 05 May 2020
Sec. Gastrointestinal and Hepatic Pharmacology

Corrigendum: TSG-6 Inhibits Oxidative Stress and Induces M2 Polarization of Hepatic Macrophages in Mice With Alcoholic Hepatitis via Suppression of STAT3 Activation

Yue-Meng Wan,Yue-Meng Wan1,2Hua-Mei WuHua-Mei Wu1Yu-Hua LiYu-Hua Li1Zhi-Yuan XuZhi-Yuan Xu1Jin-Hui YangJin-Hui Yang1Chang LiuChang Liu2Yue-Feng HeYue-Feng He2Men-Jie WangMen-Jie Wang2Xi-Nan Wu*Xi-Nan Wu2*Yuan ZhangYuan Zhang3
  • 1Gastroenterology Department, The 2nd Affiliated Hospital of Kunming Medical University, Kunming, China
  • 2Department of Occupational, Labor and Environmental Health, Public Health Institute of Kunming Medical University, Kunming, China
  • 3The Biomedical Engineering Research Center, Kunming Medical University, Kunming, China

A Corrigendum on
TSG-6 Inhibits Oxidative Stress and Induces M2 Polarization of Hepatic Macrophages in Mice With Alcoholic Hepatitis via Suppression of STAT3 Activation

by Wan Y-M, Wu H-M, Li Y-H, Xu Z-Y, Yang J-H, Liu C, He Y-F, Wang M-J, Wu X-N and Zhang Y (2020). Front. Pharmacol. 11:10. doi: 10.3389/fphar.2020.00010

In the original article, there was a mistake in Figure 2 as published. Two microphotos (A, C) were mistakenly inserted. The corrected Figure 2 appears below.

FIGURE 2
www.frontiersin.org

Figure 2 TSG-6 attenuates liver steatosis and hepatic fat accumulation: H&E staining for NC (A), AH (B), TSG-6 (C) groups; oil red O staining for NC (D), AH (E), TSG-6 (F) groups; hepatic TC (G) and TG (H) concentrations. Bars = 100 µm, #p < 0.05, ##p < 0.01, ####p < 0.0001. Six mice were used per group.

In addition, there were two errors in the Abstract. In the second sentence, the word “effective” was used. The correct word is “effects.” In the tenth sentence, the word "were" was used. The correct word was "was." Corrections have been made to the Abstract:

“Tumor necrosis factor (TNF)-α-stimulated protein 6 (TSG-6) is a secreted protein with diverse tissue protective and anti-inflammatory properties. We aimed to investigate its effects in treating mice with alcoholic hepatitis (AH) and the associated mechanisms. AH was induced in 8–10 week female C57BL/6N mice by chronic-binge ethanol feeding for 10 days. Intraperitoneal (i.p.) injection of recombinant mouse TSG-6 or saline were performed in mice on day 10. Blood samples and hepatic tissues were collected on day 11. Biochemistry, liver histology, flow cytometry, and cytokine measurements were conducted. Compared to the normal control mice, the AH mice had significantly increased liver/body weight ratio, serum alanine aminotransferase (ALT) and aspartate aminotransferases (AST), hepatic total cholesterol (TC), triglyceride (TG), malondialdehyde (MDA), hepatic macrophage infiltration, serum and hepatic interleukin (IL)-6, and tumor necrosis factor (TNF)-α, which were markedly reduced by i.p. injection of rmTSG-6. Compared to the normal control mice, the hepatic glutathione (GSH), accumulation of M2 macrophages, serum, and hepatic IL-10 and TSG-6 were prominently reduced in the AH mice, which were significantly enhanced after i.p. injection of rmTSG-6. Compared to the normal control mice, hepatic activation of signal transducer and activator of transcription 3 (STAT3) as significantly induced, which was markedly suppressed by rmTSG-6 treatment. TSG-6 was effective for the treatment of AH mice, which might be associated with its ability in inhibiting hepatic oxidative stress and inducing hepatic M2 macrophages polarization via suppressing STAT3 activation.”

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: TSG-6, alcoholic hepatitis, oxidative stress, macrophage polarization, STAT3 activation

Citation: Wan Y-M, Wu H-M, Li Y-H, Xu Z-Y, Yang J-H, Liu C, He Y-F, Wang M-J, Wu X-N and Zhang Y (2020) Corrigendum: TSG-6 Inhibits Oxidative Stress and Induces M2 Polarization of Hepatic Macrophages in Mice With Alcoholic Hepatitis via Suppression of STAT3 Activation. Front. Pharmacol. 11:569. doi: 10.3389/fphar.2020.00569

Received: 02 March 2020; Accepted: 15 April 2020;
Published: 05 May 2020.

Edited and reviewed by: Raffaele Capasso, University of Naples Federico II, Italy

Copyright © 2020 Wan, Wu, Li, Xu, Yang, Liu, He, Wang, Wu and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Xi-Nan Wu, wxnprof2011@163.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.